8-K - Annovis Bio, Inc. (0001477845) (Filer)
Published . Updated .
Key takeaways
- 8-K - Annovis Bio filed an 8-K with the SEC on Nov 5 (a notice of a material company event).
- Exposed: ANVS
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - Annovis Bio filed an 8-K with the SEC on Nov 5 (a notice of a material company event).
Directly affected
- ANVS Annovis Bio-9.4% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Annovis Bio belongs to, so it often moves with news about it.
- LLY Eli Lilly and+19.9% 30d
Eli Lilly and is a peer of Annovis Bio in pharmaceutical preparations; rivals often move on the same news.
- JNJ Johnson & Johnson+1.9% 30d
Johnson & Johnson is a peer of Annovis Bio in pharmaceutical preparations; rivals often move on the same news.
- ABBV AbbVie+11.3% 30d
AbbVie is a peer of Annovis Bio in pharmaceutical preparations; rivals often move on the same news.
- MRK Merck+5.9% 19d
Merck is a peer of Annovis Bio in pharmaceutical preparations; rivals often move on the same news.
- ABT Abbott Laboratories+13.0% 30d
Abbott Laboratories is a peer of Annovis Bio in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| ANVS | +70.85% | +67.83% | base | after close | after close | after close | after close |
| XLV | -0.05% | -0.52% | base | after close | after close | after close | after close |
| LLY | +3.64% | +3.08% | base | after close | after close | after close | after close |
| JNJ | +0.29% | -2.31% | base | after close | after close | after close | after close |
| ABBV | +2.38% | -0.72% | base | after close | after close | after close | after close |
| MRK | +1.80% | -1.52% | base | after close | after close | after close | after close |
| ABT | -6.44% | -3.65% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-05 AccNo: 0001104659-26-123467 Size: 774 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
The price since 5 Nov 2026: Annovis Bio (ANVS) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| ABBV | three days earlier | -0.72% | final price |
| ABBV | five days earlier | +2.38% | final price |
| ABT | three days earlier | -3.65% | final price |
| ABT | five days earlier | -6.44% | final price |
| Annovis Bio (ANVS) | three days earlier | +67.83% | final price |
| Annovis Bio (ANVS) | five days earlier | +70.85% | final price |
| JNJ | three days earlier | -2.31% | final price |
| JNJ | five days earlier | +0.29% | final price |
| LLY | three days earlier | +3.08% | final price |
| LLY | five days earlier | +3.64% | final price |
| MRK | three days earlier | -1.52% | final price |
| MRK | five days earlier | +1.80% | final price |
| XLV | three days earlier | -0.52% | final price |
| XLV | five days earlier | -0.05% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 62 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 36 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 41 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Lloyd Doggett bought Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 8 Sep 2026. That is 58 days before publication. Filed 5 Oct 2026. View the filing.
- Rep. Pete Sessions sold AbbVie (ABBV), worth $15,001 - $50,000 on 14 Sep 2026. That is 52 days before publication. Filed 18 Sep 2026. View the filing.
- Rep. Rohit Khanna sold AbbVie (ABBV) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 62 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 42 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 78 days before publication. Filed 9 Sep 2026. View the filing.
- Rep. Pete Sessions sold Abbott Laboratories (ABT) (held by a spouse), worth $50,001 - $100,000 on 2 Oct 2026. That is 34 days before publication. Filed 27 Oct 2026. View the filing.
- Rep. Gilbert Cisneros bought Abbott Laboratories (ABT), worth $1,001 - $15,000 on 18 Sep 2026. That is 48 days before publication. Filed 12 Oct 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Abbott Laboratories (ABT), worth $1,001 - $15,000 on 17 Sep 2026. That is 49 days before publication. Filed 30 Oct 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Annovis Bio (ANVS)
Companies carried with this story
- ANVS Annovis Bio
Annovis Bio (ANVS) is linked, with no stored direction, high confidence in the 5 Nov 2026 story “8-K - Annovis Bio, Inc. (0001477845) (Filer).” Reason on file: SEC 8-K filing -> direct issuer disclosure -> ANVS
How “8-K - Annovis Bio, Inc. (0001477845) (Filer)” reaches Annovis Bio (ANVS)
The 5 Nov 2026 story “8-K - Annovis Bio, Inc. (0001477845) (Filer)” names Annovis Bio (ANVS) because of this story.
For Annovis Bio (ANVS), the reason on file says SEC 8-K filing -> direct issuer disclosure -> ANVS
The price range for Annovis Bio (ANVS), and the dates in the story
ANVS traded between 0.94 and 1.39 across 20 sessions. The latest close on file is 1.20.
How strong the case is around Annovis Bio (ANVS)
14 out of 100
“8-K - Annovis Bio, Inc. (0001477845) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.